The 'cytokine profile': a code for sepsis

被引:346
作者
Ulloa, L
Tracey, KJ
机构
[1] N Shore LIJ Res Inst, Ctr Immunol & Inflammat, Manhasset, NY 11030 USA
[2] N Shore LIJ Res Inst, Ctr Patient Oriented Res, Manhasset, NY 11030 USA
关键词
D O I
10.1016/j.molmed.2004.12.007
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Sepsis - the most common cause of death in hospitalized patients - affects over 18 million people worldwide and has an expected 1% increase of incidence per year. Recent clinical trials indicate that therapeutic approaches effective in diseases with similar pathogenesis have a modest effect against sepsis. Although the reason for this failure remains controversial, recent studies provide new insights and promising experimental strategies. We propose that the current definition of sepsis is too broad and encompasses heterogeneous groups of patients suffering similar, but different, syndromes that are historically grouped under the general diagnosis of sepsis. Future clinical trials might define patient populations and therapeutic strategies according to the profile of expression of cytokines.
引用
收藏
页码:56 / 63
页数:8
相关论文
共 65 条
  • [1] Abraham E, 1998, LANCET, V351, P929
  • [2] Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: Time for a reevaluation
    Abraham, E
    Matthay, MA
    Dinarello, CA
    Vincent, JL
    Cohen, J
    Opal, SM
    Glauser, M
    Parsons, P
    Fisher, CJ
    Repine, JE
    [J]. CRITICAL CARE MEDICINE, 2000, 28 (01) : 232 - 235
  • [3] Cutting edge: HMG-1 as a mediator of acute lung inflammation
    Abraham, E
    Arcaroli, J
    Carmody, A
    Wang, HC
    Tracey, KJ
    [J]. JOURNAL OF IMMUNOLOGY, 2000, 165 (06) : 2950 - 2954
  • [4] Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients
    Abraham, E
    Laterre, PF
    Garbino, J
    Pingleton, S
    Butler, T
    Dugernier, T
    Margolis, B
    Kudsk, K
    Zimmerli, W
    Anderson, P
    Reynaert, M
    Lew, D
    Lesslauer, W
    Passe, S
    Cooper, P
    Burdeska, A
    Modi, M
    Leighton, A
    Salgo, M
    Van der Auwera, P
    [J]. CRITICAL CARE MEDICINE, 2001, 29 (03) : 503 - 510
  • [5] High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes
    Andersson, U
    Wang, HC
    Palmblad, K
    Aveberger, AC
    Bloom, O
    Erlandsson-Harris, H
    Janson, A
    Kokkola, R
    Zhang, MH
    Yang, H
    Tracey, KJ
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (04) : 565 - 570
  • [6] Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care
    Angus, DC
    Linde-Zwirble, WT
    Lidicker, J
    Clermont, G
    Carcillo, J
    Pinsky, MR
    [J]. CRITICAL CARE MEDICINE, 2001, 29 (07) : 1303 - 1310
  • [7] AYER LM, 1994, J RHEUMATOL, V21, P2071
  • [8] BAKER CC, 1983, SURGERY, V94, P331
  • [9] Efficacy and safety of recombinant human activated protein C for severe sepsis.
    Bernard, GR
    Vincent, JL
    Laterre, P
    LaRosa, SP
    Dhainaut, JF
    Lopez-Rodriguez, A
    Steingrub, JS
    Garber, GE
    Helterbrand, JD
    Ely, EW
    Fisher, CJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) : 699 - 709
  • [10] Current concepts in the role of the host response in Neisseria meningitidis septic shock
    Brandtzaeg, P
    van Deuren, M
    [J]. CURRENT OPINION IN INFECTIOUS DISEASES, 2002, 15 (03) : 247 - 252